纳/白金化疗的持久力量
Lucy B Xu1, Elizabeth R Smith2,3, Vasili Koutouratsas4
1Department of Biology, University of Miami, Miami, FL 33136, USA.
Cancers
|April 14, 2025
概括
尽管进行了数十年的研究,但向性癌症疗法仍难以取代纳/化疗. 这很可能是因为癌细胞对编程细胞死亡产生了抵抗力,这是这些新药准的关键机制.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 40多年前开发的taxane和化学疗法组合仍然是许多癌症的基石治疗方法.
- 尽管在了解癌症遗传学和癌症途径方面取得了进展,但向疗法并没有取代传统的细胞毒性化疗.
研究的目的:
- 调查为什么向癌症疗法没有超过已建立的税/方案的疗效.
- 提出针对性疗法的有限成功的新解释,重点关注癌细胞抵抗机制.
主要方法:
- 对癌症化疗和向治疗机制的现有文献的审查.
- 对纳税素,制剂和向治疗的拟议作用机制的分析.
- 假设编程细胞死亡途径无敏化在癌症进展中的作用.
主要成果:
- 向疗法旨在诱导癌细胞的编程细胞死亡 (亡).
- 经历瘤转变和恶性进展的癌细胞往往会使其编程的细胞死亡途径变得不敏感.
- 塔克桑和剂似乎通过物理破坏核膜来杀死癌细胞,独立于亡.
结论:
- 癌细胞中编程细胞死亡途径的脱敏化限制了向治疗的有效性.
- 税和剂的非亡作用机制有助于它们的持久疗效.
- 未来的癌症治疗开发应该探索非编程细胞死亡策略,以提高治疗结果,并可能取代或改进当前的治疗方案.
相关概念视频
Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
140
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
140
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
152
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
152
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
190
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
190


